195 Results for "

GLP Receptor

" in MedChemExpress (MCE) Product Catalog:
Products (195)

195 Results for "GLP Receptor" in MCE Product Catalog:

40
40 Publications Verification
Cat. No.: HY-P0264
CAS No.: 133514-43-9
Synonyms: Avexitide
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .
40
40 Publications Verification
Cat. No.: HY-P0014
CAS No.: 204656-20-2
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease Cancer

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
40
40 Publications Verification
Cat. No.: HY-P0014B
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
7
7 Cited Publications
Cat. No.: HY-12583
CAS No.: 1527503-11-2
Purity:  98.01%
A-366, a chemical probe, is a potent, highly selective, peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases. A-366 is also a potent, nanomolar inhibitor of the Spindlin1-H3K4me3-interaction (IC50=182.6 nM). A-366 displays high affinity at human histamine H3 receptor (Ki=17 nM) and shows subtype selectivity among subsets of the histaminergic and dopaminergic receptor families .
6
6 Cited Publications
Cat. No.: HY-101116
CAS No.: 488097-06-9
Purity:  99.67%
Target:  

GCGR

Research Areas:  

Metabolic Disease

GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .
4
4 Cited Publications
Cat. No.: HY-125824
CAS No.: 2230198-02-2
Purity:  99.85%
Synonyms: PF-06882961
Target:  

GCGR

Research Areas:  

Metabolic Disease

Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research .
3
3 Cited Publications
Cat. No.: HY-P3506
CAS No.: 2381089-83-2
Synonyms: LY3437943
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
3
3 Cited Publications
Cat. No.: HY-P3506A
Synonyms: LY3437943 TFA
Target:  

GLP Receptor GCGR

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
3
3 Cited Publications
Cat. No.: HY-P2625
CAS No.: 275801-62-2
Target:  

GCGR

Research Areas:  

Metabolic Disease

GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC50=5.8 nM) .
3
3 Cited Publications
Cat. No.: HY-P3506B
Synonyms: LY3437943 acetate
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
3
3 Cited Publications
Cat. No.: HY-P0119
CAS No.: 320367-13-3
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .
3
3 Cited Publications
Cat. No.: HY-P0119A
CAS No.: 1997361-87-1
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .
2
2 Cited Publications
Cat. No.: HY-112185
CAS No.: 2212020-52-3
Purity:  99.80%
Synonyms: LY3502970; GLP-1 Receptor agonist 1
Target:  

GCGR

Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .
2
2 Cited Publications
Cat. No.: HY-112185A
CAS No.: 3008544-96-2
Purity:  99.71%
Synonyms: LY3502970 hemicalcium hydrate; GLP-1 Receptor agonist 1 hemicalcium hydrate
Target:  

GCGR

Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .
2
2 Cited Publications
Cat. No.: HY-P81160
Synonyms: Glucagon like peptide-1 Receptor; GLP 1 R; GLP 1 Receptor; GLP 1R; GLP1r; GLP; GLP1r; Glucagon like peptide 1 Receptor; RATGL1RCP; Glip; MGC138331; GLP-1-R; GLP1R_HUMAN; Glucagon-like peptide 1 Receptor; GLP-1 Receptor; GLP-1-R; GLP-1R; Precursor.

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, ICC/IF, FC

Reactivity:  

Human, Mouse, Rat

2
2 Cited Publications
Cat. No.: HY-P700468
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuGlucagon-like peptide 1 Receptor/GLP1R, Fc; Glucagon-like peptide 1 Receptor; GLP-1 Receptor; GLP-1-R
Species:  
Source:  
2
2 Cited Publications
Cat. No.: HY-P1624
CAS No.: 197922-42-2
Synonyms: ALX-0600
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
1
1 Cited Publications
Cat. No.: HY-103546
CAS No.: 1371569-69-5
Purity:  99.48%
Target:  

GCGR

Research Areas:  

Metabolic Disease

BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.
1
1 Cited Publications
Cat. No.: HY-P1145
CAS No.: 87805-34-3
Synonyms: GLP-1 (1-37) human
Target:  

GCGR

Research Areas:  

Metabolic Disease

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.
1
1 Cited Publications
Cat. No.: HY-P3291
CAS No.: 2296814-85-0
Synonyms: ZP7570
Target:  

GCGR

Research Areas:  

Metabolic Disease

Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .